1
Clinical Trials associated with Therapeutic autologous dendritic cells(University Hospital Erlangen)Vaccination Of HLA-A1 And/Or -A2+ Stage III or IV Melanoma Patients With Tumor Peptide - Loaded Autologous Dendritic Cells That Are Generated In The Absence Or Presence Of CD40 Ligand
RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV melanoma.
100 Clinical Results associated with Therapeutic autologous dendritic cells(University Hospital Erlangen)
100 Translational Medicine associated with Therapeutic autologous dendritic cells(University Hospital Erlangen)
100 Patents (Medical) associated with Therapeutic autologous dendritic cells(University Hospital Erlangen)
100 Deals associated with Therapeutic autologous dendritic cells(University Hospital Erlangen)